MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD
The Innovation Passport will make MDMA therapy for PTSD widely available in the UK, as rapidly as possible!
The Multidisciplinary Association for Psychedelic Studies (MAPS) found that 88% of patients had a reduction in PTSD symptoms after three MDMA sessions in conjunction with trauma-focused therapy.
The organization was granted an Innovation Passport for the treatment – a UK designation that speeds up the timeline for approval of innovative medicines for life-threatening conditions (similar to Breakthrough Therapy Designations in the US, which the treatment received in 2017).
